BiotechTube

Solriamfetol + Placebo

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Excessive Daytime Sleepiness

Conditions

Excessive Daytime Sleepiness, Obstructive Sleep Apnea, Impaired Cognitive Function

Trial Timeline

May 17, 2021 → Sep 19, 2022

NCT ID
NCT04789174

About Solriamfetol + Placebo

Solriamfetol + Placebo is a approved stage product being developed by Axsome Therapeutics for Excessive Daytime Sleepiness. The current trial status is completed. This product is registered under clinical trial identifier NCT04789174. Target conditions include Excessive Daytime Sleepiness, Obstructive Sleep Apnea, Impaired Cognitive Function.

What happened to similar drugs?

1 of 4 similar drugs in Excessive Daytime Sleepiness were approved

Approved (1) Terminated (1) Active (3)
🔄Solriamfetol 150 MG + PlaceboAxsome TherapeuticsPhase 3
🔄Solriamfetol 150 mg + Solriamfetol 300 mg + PlaceboAxsome TherapeuticsPhase 3
✅Solriamfetol Oral Tablet + PlaceboAxsome TherapeuticsApproved
🔄Fibrin Sealant Grifols + EVICELGrifolsPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06170970Phase 2Recruiting
NCT04789174ApprovedCompleted

Competing Products

8 competing products in Excessive Daytime Sleepiness

See all competitors
ProductCompanyStageHype Score
Placebo + PF-03654746PfizerPhase 2
35
JZP-110Jazz PharmaceuticalsPhase 2
32
Solriamfetol 150 MG + PlaceboAxsome TherapeuticsPhase 3
44
Solriamfetol 150 mg + Solriamfetol 300 mg + PlaceboAxsome TherapeuticsPhase 3
44
Solriamfetol Oral Tablet + PlaceboAxsome TherapeuticsApproved
32
Fibrin Sealant Grifols + EVICELGrifolsPhase 3
37
ORX142 TabletsCentessa PharmaceuticalsPhase 1
33
VSF-173Vanda PharmaceuticalsPhase 2
25